Lacosamide

CAS No. 175481-36-4

Lacosamide( Erlosamide | SPM 927 | ADD 234037 )

Catalog No. M12653 CAS No. 175481-36-4

An anticonvulsant compound that enhances the slow inactivation of voltage-gated sodium channels without affecting the fast inactivation of voltage-gated sodium channels.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Lacosamide
  • Note
    Research use only, not for human use.
  • Brief Description
    An anticonvulsant compound that enhances the slow inactivation of voltage-gated sodium channels without affecting the fast inactivation of voltage-gated sodium channels.
  • Description
    An anticonvulsant compound that enhances the slow inactivation of voltage-gated sodium channels without affecting the fast inactivation of voltage-gated sodium channels; launched for the adjunctive treatment of partial-onset seizures and diabetic neuropathic pain.Epilepsy Approved.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    Erlosamide | SPM 927 | ADD 234037
  • Pathway
    Membrane Transporter/Ion Channel
  • Target
    Sodium Channel
  • Recptor
    Sodium Channel
  • Research Area
    Neurological Disease
  • Indication
    Epilepsy

Chemical Information

  • CAS Number
    175481-36-4
  • Formula Weight
    250.294
  • Molecular Formula
    C13H18N2O3
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    O=C(NCC1=CC=CC=C1)[C@H](NC(C)=O)COC
  • Chemical Name
    (2R)-2-(acetylamino)-N-benzyl-3-methoxypropanamide

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Hao JX, et al. Eur J Pharmacol. 2006 Dec 28;553(1-3):135-40. 2. Lees G, et al. Neuropharmacology. 2006 Jan;50(1):98-110. 3. Duncan GE, et al. Epilepsy Res. 2005 Oct-Nov;67(1-2):81-7.
molnova catalog
related products
  • AZD-1305

    AZD-1305 is a novel antiarrhythmic agent that predominantly blocks the rapid component of Ikr.

  • VX-150

    VX-150 is a highly selective NaV1.8 inhibitor relative to the other sodium channel subtypes (>400-fold).

  • AZD 7009

    AZD 7009 is a novel antiarrhythmic agent that inhibits the late sodium current in CHO K1 cells expressing hNav1.5 with IC50 of 11 uM.